Charles River Laboratories (CRL) Tops Q2 EPS by 16c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $351.87 +3.94%
EPS Growth %: +22.2%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
FUSE, INM, TRI, More
EPS Growth %: +22.2%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.62, $0.16 better than the analyst estimate of $1.46. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $571.33 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.85-$6.00, versus prior of $5.77-$5.92 and the consensus of $5.84. Sees revenue growth of 19-21% versus 18-20%.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- JELD-WEN Holding, Inc. (JELD) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Essential Utilities, Inc. (WTRG) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
